Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sure you say a few obvious facts about TXTM's PAST. But much of what you say is pure SPECULATION.
That's what I thought. Oblously you don't know the difference between ASSUMING something about TXTM/RSAMMD and KNOWING. You ARE ASSuming and SPECULATING about what TXTM/RSAMMD
may or may not have. Knowing requires first hand experience.
"I absolute do know what they have. Nothing. I'm not assuming anything. If there was something wouldn't there be revenues over the last few years? Why would the stock be sitting in 000's if it really had something that everyone wants and needs? Why would it be broke? Why wouldn't it report? 100 percent clear and certain this is another stock selling scheme in Pink land.
Even more pathetic about TXTM is still called MOBILITY. As in the driver app that supposedly nobody had. After that didn't work they went dark for 2 years. Stock didn't trade and then they came up with a story in the MJ industry. LMAO!!!!"
So, because RSAMMD is not a Household name all over the world it must be a scam? LMAO
Have you EVER considered just for a second that you might be wrong about TXTM or RSAMMD? Or anything?
Yeah, I didn't think so......LMAO!!!!
I have seen "Phytofare" brand from other sources other than TXTM over the years. This is the same technology they are using now with RSAMMD.
Just because many of TXTM/PLPL ventures have failed in the past that doesn't mean they will never succeed.
All you can say is what you speculate TXTM doesn't have from what you have seen.
BUT YOU DON"T KNOW WHAT THEY HAVE.....PERIOD! So you ASSume they have nothing. LMAO!!!!
Show me proof TXTM has nothing. Maybe RSAMMD is not what you think it is?
Still holding. Still hoping. Still dreaming. Good luck to all!
You sure do have a lot of questions about TXTM. That's what I thought. No answers. All you know is what HAPPENED, and then you speculate as to why. Thats all you got. You say you know the players. Prove it!You don't know TXTM's future anymore than anyone else.
The Phytofare is not TXTM's baby. You should know this by now-Five years+ continuously bashing these companies. For what?
As for the Blockchain and TXTM, who knows. it didn't work out for some reason. Why can't you just leave it alone. the past is gone-done.
Yes I see a pattern. You might see it if you look in the mirror, hahahahahahah!!!
What do you know about TXTM's future? NOTHING!!! How could you? You do nothing but look into the past.
The future is bright for TXTM. But not for you because you can't take your eyes off the rear view mirror. LMAO!!!
TXTM will get the license. You are living in the past man! Let it go. New company. Duffield"s long awaited dream WILL come to fruition! I can't wait till you and all the naysayers get proven wrong!!!
All you have done is make predictions about the future of TXTM. Wether any of those come true is irrelevant.
But you did say you have been to the TXTM office address. So why can't you provide a picture? Is it because you are nowhere near there, and never were?
Scam? Looks pretty real to me
http://us.c-c-l.com/products/branded-ingredients/plandai-biotechnology/phytofare-.htm
Why do you keep posting this? What is the relevance to TXTM?
Thanks. I'm holding for Copper before I Take any profits. But I believe TXTM will go much higher If everything plays out like it is expected to, so I will be holding a substantial core for Silver and beyond. GL
2013? Wow! now you are really reaching. That's ancient history man. New company now. New business. New CEO. New acquisitions. No comparison. Time for TXTM to SHINE! Time for you to move on don't you think?
Based on your post history here about TXTM IMO you wouldn't know a positive thing if it sat in your lap and wiggled :0)
This is the 1 year anniversary of the last big run to .0056. Been accumulating since then.I now have 35M shares. It's been a rough ride but I never lost faith in TXTM. Hugh things coming. Now is our time! GLTA
We could get news before market opens right, since SA is 7 hours ahead of west coast time?
If the bill goes through that's going to be huge, but the real fun begins when we get the MJ license!
Good luck to all!
Just got email from TXTM:
Adoption of the Medical Innovation Bill now on GOV'T DOCKET for this Wed.
(originally scheduled for Oct.13th, as per Sept.13th Briefing on Cannabis Guidelines.)
Wed, Nov.15th
Portfolio Committee on Health, (National Assembly), [Briefing by the Medicines Control Council (MCC) on the Cannabis Guidelines; Consideration and adoption of the Medical Innovation Bill], Committee Room M46, Ground Floor, Marks Building, 09:30
Links:
Schedule of Parliamentary Committee Meetings dated 14 November 2017 (14 pages) https://t.co/xlRci0pIjO pic.twitter.com/daaUsE471K
— Parliament of RSA (@ParliamentofRSA) November 13, 2017
Nope. I got in right before the run to .0056. My first buy was .0007 :)
Now, why are you wasting your life here?
$TXTM website has been updated with info on Cannabis Biosciences. Sounds like they have done their homework and have a definitive plan.Check it out. If they can pull this off we got a game changer here
Protext Mobility, Inc. recently added ownership of Cannabis Biosciences Inc. to its portfolio as a wholly-owned subsidiary. Cannabis Biosciences was incorporated in 2013 to develop non- psychoactive medicines from live cannabis plant and will focus on developing cannabis extracts under legal government licenses and permits which the Company is currently pursuing.
Using Plandaí’s proprietary processing and extraction technology, the company intends to commence investigations in conjunction with independent researchers to develop and validate a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The hypothesis is that the resultant extract will have similar, superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive.
Live cannabis leaf is inherently non-psychoactive. It is the process of drying and heating the leaf that metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. In developing pharmaceutical applications, the commonly used super critical extraction method also uses extreme temperatures that causes THC to retain these properties. Our process, which uses live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential.
Where most pharma companies have chosen to focus on the non-psychoactive CBD chemical, we believe that this strategy limits the potential medical benefits. Our full profile, non-psychoactive extract is intended to give researches all of the benefits of cannabis with none of the unwanted side effects.
Introduction to Cannabis
The plant Cannabis sativa produces over 421 chemical compounds including 80 terpeno-phenol compounds (phytocannabinoids) that have not been detected in any other plant. Currently commercial attention has been focused on producing extracts of ??- tetrahydrocannabinol (??- THC) which is the most psychotropic component and rapidly metabolizes in the body to a number of oxygenated products; but specifically binds to the G-protein- coupled CB1and CB2 neuron receptors.
The major problem in the current world of medical marijuana is the inability of the industry to deliver botanical cannabinoid agents with therapeutic action in a validated dosage and without psychotropic side effects.
As the industry of medical marijuana has rapidly grown in the United States and many other parts of the world over the past few years so have the scientific challenges and responsibilities. Numerous, largely unregulated, botanical cannabis products sold through licensed dispensaries have entered the market. Medicinal applications range from formulated foods, liquids, capsules, vapour pens and inhalers, or simply smoking the dried flower. The claims are disparate, unsupported by clinical trials, and fail to take into account varying dosage levels or differences in chemical values of the different strains.
This new industry has not addressed or overcome multiple challenges associated with the development of a safe wellness product. These products, targeted for disease prevention rather than recreational use, still rely mainly on psychoactive oral administration as the only viable route. The undesirable consequences are disturbing and heavily stigmatized in most societies.
For cannabinoids to become an approved FDA botanical drug, the questions of psychoactivity, metabolization, excretion, target tissue uptake, and residence time must be clinically addressed.
The Endocannabinoid System
The endocannabinoid system (ECS) is a group of endogenous cannabinoid receptors located in the brain and throughout the central and peripheral nervous systems. The ECS system is responsible in controlling a variety of physiological processes including appetite, pain-sensation, mood and memory. Evidence suggests that endocannabinoids may function as both neuromodulators and immunomodulators in the immune system where they seem to serve an autoprotective role to ameliorate muscle spasms, inflammation, and other symptoms of multiple sclerosis and skeletal muscle spasms.
The endocannabinoid system is a main target for pharmacotherapy though it presents numerous treatment challenges. We know that the cannabinoid receptors are activated by endogenous ligands and that the mechanisms of the endocannabinoid biosynthesis and inactivation constitute the endocannabinoid release in the central and peripheral nervous system, pain perception, and cardiovascular, gastrointestinal and liver functions.
The Company’s strategy is to both improve the efficacy and manipulate the endocannabinoid system through delivering a complex of highly bioavailable non- psychoactive cannabinoids and polyphenols. It is suggested this may include targeting of the cannabinoid receptors located outside the blood brain barrier and modulating the endocannabinoid system. We further propose eliminating of the psychotropic side effects of ??- tetrahydrocannabinol by retaining it in its natural form: ??- tetrahydrocannabinol acid (??-THCA), cannabidiolic acid (CBDA) and ?? tetrahydrocannabivarin (??-THCV). Research shows that these compounds exert multiple actions through mechanisms related to the modulation of the endocannabinoid system. Together with cannabidiol (CBD), which exerts several safe positive pharmacological effects in inflammation, diabetes and cancer, ??-THCV has demonstrated the pharmacological profile of a CB1 antagonist with obesity.
Hypothesis
The hypothesis follows the scientific evidence showing that different diseases (neurodegenerative, neurotrauma, cancer) share common factors with inflammation, oxidative stress and excitotoxicity.
We propose that the known wide distribution of the endocannabinoid system, and particularly the link between the endocannabinoid system, the immune system, the oxidative stress reactions (antioxidant properties of cannabinoids), excitotoxicity (modulation of excitatory glutamatergic transmissions), neuroinflammation, neurodegeneration, the MAPK signaling pathway and the PI3K–Akt pathway, all support a palliative action from Phytofare ® cannabinoid complex including for the treatment and prevention of Parkinson, Alzheimer, epilepsy, Multiple Sclerosis, traumatic brain injury and cancer. It is argued that the main target for the mechanisms of action is the CB2R, being CB1R also involved but mainly in the cognitive and motor effects.
Cannabis Biosciences will utilize Plandai’s processing and extraction protocols using leaf and flower of the live cannabis plant which is expected to yield a non- psychoactive complex of the entire plant phytonutrients, including phytocannabinoids, cannabinoid acids and polyphenols. The resultant extract will be entrapped in the liposome system, thereby conferring high bioavailability, efficacy and protection through the stomach and liver to the plasma.
Phytofare® phytocannabinoids are expected to travel through the blood-brain barrier where cannabinoids have been shown to protect the brain in a variety of conditions (Rom et al., 2013). Pharmaceutical drugs have demonstrated restricted ability to cross the blood brain barrier and thereby have shown to have little to no benefit in treating neuron disorders (Avraham et al., 2013).
It is postulated that the Phytofare ® phytocannabinoid complex will exhibit no psychoactive activity because the conditions for the formation of THC from THCA and THCB acids will not be introduced, and it is already proven that the acids in their natural state are not psychoactive.
In conclusion, it is expected that the high bioavailability characteristics, the presence of the phytocannabinoids precursors (acids) with polyphenols and terpenes, together with the known action of cannabinoids in the immune system, will translate to an efficient physiological action for the treatment of neurodegenerative diseases and cancers.
General Objective
The objective of this project is to produce an FDA approved botanical drug/dietary supplement containing Phytofare ® non-psychoactive phytocannabinoids entrapped in liposome with high bioavailability and efficacy for the treatment and prevention of neurodegenerative diseases and cancer. The project will incorporate the following elements:
Controlled Environment Cultivation
The growing of stable and specific cannabis specie is critical to ensuring pharmacologic consistency and repeatability of the final extract. The chemical profile of cannabis can vary not only strain-to- strain, but also from fluctuations in growing temperature, light, nutrients, and airflow. The project will require the cannabis plant to be grown in a controlled environment cultivation system.
Cannabis Biosciences intends to build on the successful farming model put in place by the parent company, Plandaí Biotechnology, in South Africa. This project developed the standards in farming husbandry and methodologies with green tea that have established a platform that should allow a Phytofare® extract from cannabis plants to be successfully grown in a specific and controlled environment.
Extraction, Chemical Profile, and Nano-Entrapment
The second phase of the project will involve the creation of a Phytofare ® phytocannabinoid complex from live cannabis flower and leaf; with the processing system located at an approved research facility. Our protocols for producing the extract are specific to the cannabis plant and are free of solvents or chemicals.
During the various processing stages of cavitation and sonoluminescence, the complex of phytonutrients and phytocannabinoids are converted into highly- bioavailable amorphous crystals, expressed in a unique cis- and trans-isomer forensic molecular footprint. The resulting Phytofare® complex is then entrapped in liposome for further protection of molecules and then delivered in capsules for oral consumption. Detailed analysis and chemical profiling will support the final product.
Biological Assessment
Following the initial profiling, the project will evaluate the antioxidant activities of the complex by means of in vitro and in vivo (murine) studies. This phase includes evaluating anti-inflammatory and antioxidant activities; toxicity and mutagenicity; bioavailability and absence of psychoactivity.
Neurological Diseases and Cancer
The blood-brain barrier (BBB) is formed by highly specialized endothelial cells that line brain capillaries and transduce signals from the vascular system and from the brain. The medical challenges of delivering an effective therapy to the brain is formidable as the blood–brain barrier (BBB) is a dynamic barrier protecting the brain against invading organisms and unwanted substances.
It is also the most important barrier impeding drug transport into the brain via the blood circulation. Despite the rapid development in our understanding of the molecular structure of components of the BBB, our knowledge in receptor expression at the BBB, advances in medical technology, and breakthroughs in nanotechnology- based approaches, many of the brain or central nervous system associated diseases remain under-treated by effective therapies.
A feature of the BBB is its low and selective permeability to molecules which can be attributed to its unique biological characteristics and undergo significant changes when the brain is developing a neurological disorder, in inflammatory conditions or under attack by pathogens.
Phytocannabinoids have been researched to effectively pass through the BBB and have been shown to have both anti-inflammatory activities and neuron free radical scavenging. Specific in vitro and mouse modelling studies are required to confirm that Phytofare® phytocannabinoids are transported into the brain via the blood circulation and provide both anti-inflammatory activities as well as perform oxygen free radical scavenging and support the endocannabinoid system. This could also include new botanical strategies for treating diseases like Alzheimer's and Parkinson's.
Anyone see the latest PR from PLPL. Pretty much lays it all out what's coming. Including the Type 2 Diabeties clinical trials, and producing a non-psychoactive cannabinoid complex from live cannabis plants. I think TXTM is going to take many by surprise. Not me because I can see what's coming, and it's going to be awesome :)
Plandai Biotechnology Names Callum Cottrell-Duffield as New Chief Operating Officer
BY Market Wire
— 8:00 AM ET 03/27/2017
LONDON, UNITED KINGDOM -- (Marketwired) -- 03/27/17 -- Plandaí Biotechnology, Inc. ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that Callum Cottrell-Duffield has been named President and Chief Operating Officer, replacing the Company's founder, Roger Baylis-Duffield, who will remain Chief Executive Officer. Mr. Cottrell-Duffield has been serving as Vice President of Sales and Marketing.
Mr. Cottrell-Duffield's new duties will include managing the portfolio of companies under the Plandaí umbrella on a day-to-day basis, including overseeing production and sales while coordinating the various research projects and ensuring that the Company's financial reporting and compliance obligations are met.
Callum Cottrell-Duffield, Chief Operating Officer of Plandaí, commented, "It is a tremendous honor to take the reins of the day-to-day operations of Plandaí from a man I deeply respect as a visionary and love as a father. With Plandaí now shifting from a pure research company to operations and sales, it makes sense for Roger to concentrate his efforts in those areas where he is most passionate. As a scientist, he feels he can best serve the company in spearheading our clinical trials and new product development."
Roger Baylis-Duffield added, "Callum has been with the company since its inception. He was the first to set foot on Senteeko, and he spent months clearing brush and living under fairly stringent conditions to make our vision a reality. As we moved into production last year, Callum has led our sales and marketing team with great success. I am confident he will lead the Plandaí group with similar result. I will be turning 74 in a few months, and there is a tremendous amount of research to complete before they will let me retire, so this change at the top is both timely and needed."
Mr. Baylis-Duffield, as Chief Executive Officer, will continue to guide the overall company objectives while also managing the research projects and clinical trials involving the flagship Phytofare® Catechin Complex. These studies include a health and wellness trial for commercial poultry production, and a human study in Mauritius to validate the improvement of hemoglobin and glucose levels in type II diabetics. In addition to these studies, Mr. Baylis-Duffield will be completing the production specifications for a bioavailable complex of citrus bioflavonoids and limonoids, and an additional carotenoid complex recovered from live tomato. Finally, Mr. Baylis-Duffield wants to establish the platform for producing a non-psychoactive cannabinoid complex from live cannabis plants over the coming year.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the green tea on its farms in South Africa, to producing its proprietary Phytofare® catechin extract in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Even if what you are saying is true,that was then. This is now. A concept that looks like you will never understand. The company is evolving from a developing company into a revenue producing Biotech/MJ Biotech company. You will never get anywhere in life if you are constantly looking in the rear view mirror. Get over it! Move on. But I have a feeling you will still be here playing that same broken record even after millionaires have been made
Here is what you're missing:
"Under the terms of the Exchange Agreement, Plandaí became the majority owner of Protext with Plandaí SA becoming the successor issuer to Protect for reporting and accounting purposes"
Plandai Biotechnology is majority owner of Plandai Biotechnology South Africa(TXTM)which has two subsidiaries,Plandai Biotechnology SA and now Cannabis Biosciences.
Thank you! People can be so short sighted. The PR today confirms what we have been speculating for months now. TXTM is a MJ biotech company.
I can't think of a better time to be in TXTM or any MJ Biotech.This sector is red hot and is just beginning to build up steam. Right place right time.Also Phytofhare is for real. Just ask the makers of Nutribullet. The type 2 Diabeties human clinical trials with Phytofare will be huge too IMO. Patience is key. Good luck to all
I got one too here is copy:
Hi, just wanted to inform you of the below tweet and upcoming update
https://twitter.com/protxtm
Protext Mobility? @protxtm 53
$TXTM Exciting #shareholdersupdate coming stay tuned for next week. #Investors #traders #shareholders
-------- Original Message --------
Subject:
From: <info@protextm.co>
Date: Fri, March 03, 2017 6:49 am
To: xx
Good Morning, below is a link to today's PR for the most recent update. There should be additional updates soon.
http://www.marketwired.com/press-release/protext-mobility-caps-off-week-meetings-mauritius-with-visit-state-house-meeting-with-otc-txtm-2200302.htm
Have a nice weekend.
I don't know man. Not lookin good for under .0015, but anything is possible in the otc. This thing has been pretty much been going sideways for almost 2 months. Lots of pressure building. Cause and effect. Can you hear that low rumble.....She's gonna blow!!! LOL
Oh yeah! I like your style. I would add to that. "Human clinical trials now underway for type 2 diabetes in Mauritius"
Picked up a partial fill 350K @.0014 this AM . Sweet! This is just icing on the cake. I'm now holding 22M+ for the ride to copper and beyond:)
Lol. Won't be long and you'll be saying "Dip to .01 then we run to silver"
New Tweet- TNT Fat burner, with Phytofare :)
http://www.tntfatburner.co.uk/product/tnt-fatburner/#tab-nutritional-information
This is great news!
Also according to OTC Short Report the short volume is way down.
Date Close High Low Volume Short Volume % of Vol Shorted
Mar 06 0.0021 0.0022 0.0018 51,332,694 4,952,603 9.65%
Mar 03 0.0021 0.0028 0.0015 208,305,715 72,503,410 34.81%
Mar 02 0.0014 0.0019 0.0013 60,064,064 22,773,818 37.92%
Mar 01 0.0017 0.002 0.0015 59,036,207 34,375,240 58.23%
Feb 28 0.0016 0.0017 0.0014 37,672,786 3,903,697 10.36%
Feb 27 0.0014 0.0019 0.0014 82,774,051 9,608,679 11.61%
Feb 24 0.0017 0.002 0.0015 62,266,039 23,150,396 37.18%
Feb 23 0.0018 0.0021 0.0017 28,817,760 7,816,152 27.12%
Feb 22 0.00189 0.0023 0.0015 73,072,685 26,748,757 36.61%
Feb 21 0.0018 0.0018 0.0013 105,858,579 33,196,310 31.36%
Feb 20 0.0016 0.0016 0.0016 0 0 0%
Feb 17 0.0016 0.0019 0.0014 57,475,713 335,000 0.58%
Feb 16 0.0017 0.0024 0.0017 37,211,822 10,404,461 27.96%
Feb 15 0.0022 0.0025 0.0014 65,761,022 20,309,867 30.88%
Feb 14 0.0016 0.0017 0.0012 92,964,335 21,439,984 23.06%
Feb 13 0.0016 0.0019 0.0015 60,882,068 2,679,826 4.40%
Feb 10 0.0018 0.0021 0.0017 91,741,208 19,034,763 20.75%
Feb 09 0.002 0.0024 0.0017 89,776,087 28,805,061 32.09%
Feb 08 0.0017 0.0024 0.0015 133,277,949 40,672,557 30.52%
Feb 07 0.0017 0.00231 0.0013 317,737,955 94,581,391 29.77%
Feb 06 0.0023 0.0032 0.00209 122,695,767 24,254,958 19.77%
Thanks! Great DD. Wow! Talk about a sleeping Giant. Glad I found this hidden Gem!
I agree this thing is coiled and ready to blast off
Everything seems to be falling into place. Awaiting much anticipated PR from $TXTM.
Tweets are great, but an update in the form of a PR or a even a Filing what will make this "Real" and we fly!
I am in to win w/17+Mil :)
Regarding the Diego Pellicer connection, Nice! But that PR was from Feb 2012.
How do we know Jamen Shively is still involved? Has there been any other mention of this since by Plandia?
I am all in here and loading these dips! Good luck to all, we got ourselves a real GEM here.
"Huge difference between a great year - which according to The Clown already happened last year - then saying that the following year would pale in comparison to the last."
You are wrong about this Vanis did not say it like you said.
Here is the quote:
"however, that growth, we believe, will potentially pale in comparison to what we have planned for the next five months going forward."
HOUSTON, April 22, 2015 (GLOBE NEWSWIRE) -- Minerco Resources, Inc. (OTC:MINE), parent company of Level 5 Beverage Company, Inc., the makers of VitaminFIZZ®, announced that Level 5 has purchased a 10% equity position in the VitaminFIZZ Brand. Level 5 holds the rights to purchase up to 56% interest in the brand, over the next five years. This acquisition is in addition to the existing licensing agreement that currently entitles Level 5 to 51% of the net revenues and operational control of the brand.
"This procurement has come at a very opportune time for Level 5 as our company and flagship product are beginning to reach a critical mass in initial key markets. This is another step in our strategy to increase shareholder value by continuing to acquire cash flowing assets," said V. Scott Vanis, Minerco's Chairman and CEO. "This new equity position in VitaminFIZZ offers us many advantages including easier access to traditional financing, indefinite guaranteed ownership of the brand and increased equity for our shareholders. Additionally, the acquisition will set a benchmark of verified current valuation of VitaminFIZZ. We have experienced impressive growth in just seven short months; however, that growth, we believe, will potentially pale in comparison to what we have planned for the next five months going forward."
Vanis never promised anything. You and many here bought Mine based on Assumptions, Not facts or promises. So there is nobody to blame but yourself. Here is the quote:
"however, that growth, we believe, will potentially pale in comparison to what we have planned for the next five months going forward."
HOUSTON, April 22, 2015 (GLOBE NEWSWIRE) -- Minerco Resources, Inc. (OTC:MINE), parent company of Level 5 Beverage Company, Inc., the makers of VitaminFIZZ®, announced that Level 5 has purchased a 10% equity position in the VitaminFIZZ Brand. Level 5 holds the rights to purchase up to 56% interest in the brand, over the next five years. This acquisition is in addition to the existing licensing agreement that currently entitles Level 5 to 51% of the net revenues and operational control of the brand.
"This procurement has come at a very opportune time for Level 5 as our company and flagship product are beginning to reach a critical mass in initial key markets. This is another step in our strategy to increase shareholder value by continuing to acquire cash flowing assets," said V. Scott Vanis, Minerco's Chairman and CEO. "This new equity position in VitaminFIZZ offers us many advantages including easier access to traditional financing, indefinite guaranteed ownership of the brand and increased equity for our shareholders. Additionally, the acquisition will set a benchmark of verified current valuation of VitaminFIZZ. We have experienced impressive growth in just seven short months; however, that growth, we believe, will potentially pale in comparison to what we have planned for the next five months going forward."
Vanis does not and can not give you or anyone else your own expectations. He always says what he Believes....His own opinions on how the company is doing and what he expects the company to do in the future. Then you and everyone else forms thier own expectations from what they hear .... And from thier own personal personal perspective. That is how it really works.
"You're overlooking the Fact that it has been the CEO solely who has laid out the expectations..
And perhaps SS1 saying we are due for a 1,000% run, but most everything I've read on this board has originated with the Company, and now people are finally getting hip to what is going on, and calling Vanis out on his misleading language.."
I talked to the guys at Avanzar recently and I asked How Fizz was doing. They said Fizz is "holding it's own". and "Volume is increasing". So Fizz is not struggling IMO. But it is very Capital Intensive. That's why we need the "Work Horse" to help get it off the ground and profitable faster.
"I can only imagine that THC will burn more money than it will make.. Just like VitaminFIZZ is doing.. Fizz is struggling, it needs the help of some miracle 'work horse' to bail it out..
When on the CC Ezra and Vanis told us that Fizz was the work horse, or was going to do the 'Heavy Lifting..'"
You've never heard of Rocky mtn. High hemp infused beverage(Distributed by Avanzar)?. I'd say there is a lot of interest in hemp beverages. Did you see what happened to the stock when they announced Rocky mtn high was available on Amazon? THC's CBD is from hemp. Perhaps you should do a little DD on Hemp and CBD before you form your opinions?
"I've never heard one person ever express interest in such a product, and have never seen one in a store..
Its not going to be anything spectacular.. #Markit
First of all, Minerco doesn't even have the money to keep Fizz going without the help of some 'work horse' game changer, so where are they going to get the money to produce some CBD tea..? "
That IS the case. And I don't think The Herbal Collection' target market is Stoners. This "THC will not get you high.
"Even if that is the case... Almost all of my friends are 'stoners' and I have never herd them once express interest in a CBD herbal tea.."